Cefotiam, a new semisynthetic cephalosporin, has a broad spectrum of activity against most gram-positive organisms as well as gram-negative aerobic bacilli such as Klebsiella, Proteus, Haemophilus, Enterobacter, and Citrobacter species (5, 7, 9) . The antibiotic is also active against Ilactamase-producing strains of Staphylococcus aureus and Haemophilus influenzae (9) . Cefotiam has been shown to attain high levels in the lung tissue of animals (8) . Because of its antimicrobial spectrum, we evaluated the efficacy and safety of the drug in the treatment of lower respiratory tract infections.
Hospitalized patients 18 years of age or older requiring parenteral antibiotics were entered into the study. Consent was obtained from all patients. Selection criteria for these studies included patients (i) with a presumptive diagnosis of acute pulmonary infection based on the presence of fever, cough, dyspnea, and infiltrate on chest roentgenogram, and (ii) with moderate to abundant gram-positive cocci, gramnegative bacilli, or gram-negative coccobacilli and polymorphonuclear leukocytes on Gram stain examination of the sputum. Exclusion criteria included patients (i) with an allergy to cephalosporins, penicillins, or local anesthetics of the amide type, (ii) with hepatic dysfunction with a serum bilirubin or serum glutamic oxalacetic transaminase greater than twice normal, (iii) with renal impairment with a serum creatinine greater than twice normal, (iv) who received antimicrobial therapy within the previous 48 h, (v) with the need for concomitant antimicrobial therapy, (vi) who were pregnant, (vii) with impaired immunologic function receiving immunosuppressive therapy, and (viii) who were seriously ill and were likely to die within 72 h.
The dosage of cefotiam varied from 0.5 g every 6 h to 2 g every 6 h, depending on the severity of the illness. The patient must have received at least 4 days of cefotiam therapy to be considered evaluable. Pathogens isolated before therapy had to be susceptible to cefotiam.
Patients were followed and examined daily through the end of therapy. Hematologic, hepatic, and renal function tests were performed. Adequate sputum specimens (containing more than 25 leukocytes and less than 10 epithelial cells * Corresponding author.
per high-power field as determined with Gram stain) were obtained from all patients for Gram stain and culture (3). Chest roentgenograms and blood cultures were performed before therapy and were repeated as deemed appropriate. Cure was defined as complete eradication of the signs and symptoms of acute lower respiratory tract infection with bacteriologic clearance. Improvement was defined as alleviation of the signs and symptoms with or without bacteriologic clearance. All bacterial isolates from patients were tested for susceptibility to cefotiam with a 30-,ug disk, using the standard disk diffusion technique (1) .
Chest roentgenograms were obtained on 35 patients upon admission. Of the 29 evaluable patients, all had infiltrates on chest roentgenograms except for 1 patient with severe bronchitis. A total of 20 patients had lobar pneumonia, 5 patients had bronchopneumonia, and 1 patient each had lobar pneumonia with empyema, lobar pneumonia with a lung abscess, and an infiltrate compatible with aspiration pneumonia. A total of six patients were not evaluable; two patients of the nonevaluable group had Pseudomonas aeruginosa isolated from their sputum cultures and required broader antibiotic therapy, one patient had severe chronic obstructive lung disease with H. influenzae pneumonia and died on day 3 of therapy, one patient had congestive heart failure with S. aureus pneumonia and died on day 3 of therapy, one patient developed meningitis and required a change in therapy after one dose of cefotiam, and one patient had pulmonary edema rather than pneumonia and received one dose of cefotiam.
A patients (90%); 8 patients were cured, and 18 patients improved with completion of cefotiam therapy as assessed by clinical parameters and chest roentgenograms. The latter 18 patients received further oral therapy after parenteral therapy to complete a minimum of a 10-day course of antibiotics. The oral therapy was individualized to the specific organism isolated from each patient and included oral penicillin, ampicillin, amoxicillin, cephalexin, or cefaclor. The duration of cefotiam therapy ranged from 4 to 14 days, with a mean of 7 days. There were three failures: one patient with mixed Enterobacter agglomerans-Pseudomonas (not P. aeruginosa) pneumonia developed progressive pleural effusions and required additional antimicrobial therapy; one patient with combined H. influenzae-S. pneumoniae-Klebsiella pneumoniae pneumonia showed no clinical improvement after 6 days of cefotiam, and therapy was changed; and one patient, an elderly woman who had mixed K. pneumoniae-Enterobacter pneumonia, died on day 6 of therapy and was found to be superinfected with Pseudomonas pneumonia. One patient with S. pneumoniae pneumonia and bacteremia improved with cefotiam therapy but later developed a P. aeruginosa superinfection that led to septic shock and subsequent death.
No patient had any serious adverse reaction related to the drug. There was no evidence of renal or hepatic dysfunction as a result of cefotiam therapy. Two patients developed mild phlebitis. After treatment, four patients were found to be colonized with gram-negative organisms, three of them with P. aeruginosa.
Cefotiam is a new broad-spectrum cephalosporin with an in vitro spectrum similar to that of cefamandole (5, 7, 9) . In contrast to cefamandole, which required more frequent administration, clinical and bacteriologic cures have been reported in a study of skin and soft-tissue infections in which cefotiam was administered every 12 h (2) . In animal studies, cefotiam attains very high tissue concentrations in the kidneys, liver, and lungs (8) . The therapeutic efficacy of cefotiam may be due to its high affinity for penicillin-binding proteins (4) .
In this study, cefotiam was a safe, well-tolerated, and effective antibiotic for non-life-threatening lower respiratory tract infections, with a low incidence of adverse effects. A disturbing problem was the relatively large number of posttherapy superinfections (2) and colonizations (3) that were caused by P. aeruginosa. This may pose a problem in the treatment of pneumonia in seriously ill patients in situations such as an intensive-care-unit setting, where superinfection is common (6) . Nevertheless, in lower respiratory tract infections due to susceptible organisms, when aminoglycosides must be avoided, cefotiam is an alternative drug that can be administered safely to mildly to moderately ill patients when a parenteral antibiotic is indicated. Further studies are warranted to determine whether cefotiam can be administered every 8 or 12 h in the therapy of lower respiratory tract infections.
